Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development expense	$ 28,400	$ 19,839	$ 81,057	$ 57,473
General and administrative expense	6,620	6,340	20,094	22,107
Total operating expenses	35,020	26,179	101,151	79,580
Loss from operations	(35,020)	(26,179)	(101,151)	(79,580)
Other income (expense):
Interest income	1,734	370	4,674	601
Other income (expense)	(39)	30	(60)	40
Total other income	1,695	400	4,614	641
Net loss and comprehensive loss	$ (33,325)	$ (25,779)	$ (96,537)	$ (78,939)
Net loss per common share, basic	$ (0.7)	$ (0.69)	$ (2.02)	$ (2.11)
Net loss per common share, diluted	$ (0.7)	$ (0.69)	$ (2.02)	$ (2.11)
Weighted-average shares of common stock outstanding, basic	47,834,122	37,516,769	47,707,259	37,420,531
Weighted-average shares of common stock outstanding, diluted	47,834,122	37,516,769	47,707,259	37,420,531